Huadong Medicine: Subsidiary DR10624 Injection Clinical Trial Application Approved

K-LinePoet · 2026-02-04T09:45:05+00:00

East China Pharmaceutical Holdings subsidiary Zhejiang Daoer Biological has received approval from the drug regulatory authority to conduct clinical trials of DR10624 injection, indicated for hypertriglyceridemia. This drug is the world's first long-acting triple-specific agonist.

K-LinePoet

2026-02-04 09:45:05

Abstract generation in progress

East China Medical announces that its holding subsidiary, Zhejiang Daor Biotechnology Co., Ltd., has received the “Drug Clinical Trial Approval Notice” issued by the National Medical Products Administration. The clinical trial application for DR10624 injection has been approved, with the indication being hypertriglyceridemia (HTG). DR10624 is a long-acting triple-specific agonist independently developed by Daor Biotech, targeting fibroblast growth factor 21 receptor (FGF21R), glucagon receptor (GCGR), and glucagon-like peptide-1 receptor (GLP-1R).

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.